Emistat

®
Oral Solution
Ondansetron Hydrochloride USP

Composition
Active ingredient: Ondansetron
Emistat® oral solution: Each 5 ml contains Ondansetron Hydrochloride USP equivalent to Ondansetron 4 mg.

Properties and effects

Emistat® is a selective 5-hydroxytryptamine-3 (5-HT3) receptor antagonist with anti-emetic activity.
Pharmacokinetics
Absorption
Emistat® is well absorbed from the gastrointestinal tract and undergoes some first-pass metabolism. Mean bioavailability in healthy subjects is
approximately 56% and bioavailability is also slightly enhanced by the presence of food and at higher doses but unaffected by antacids.
Distribution
Emistat® is distributed with volume of distribution 1.9-2.6 L/Kg, indicating that much of the drug is taken up by body tissues. Circulating drug
also distributes into erythrocytes. Plasma protein binding of Emistat® is 70% and crosses membranes readily.
Metabolism
Biotransformation pathways involve the primary metabolic pathway is hydroxylation on the indole ring followed by subsequent glucuronide or
sulfate conjugation.
Elimination
Emistat® is excreted in the urine (approximately 65%) and feces (35%) after extensive hepatic metabolism. The plasma half-life of Emistat® is
3.5 hours.
Indications and usage
Emistat® is indicated for the prevention and treatment of post-operative nausea and vomiting, and for the management of nausea and vomiting
induced by cytotoxic chemotherapy and radiotherapy.
Dosage and administration
Chemotherapy induced Nausea and Vomiting

Age Category Oral Solution

Highly emetogenic cancer chemotherapy: 30 ml (24 mg) Emistat Oral Solution
administered 30 minutes before start of emetogenic chemotherapy.
Adults/ Geriatric/ Child of 12
Moderate emetogenic cancer chemotherapy: 10 ml (8 mg) Emistat Oral
years or over
Solution administered 30 minutes before start of emetogenic chemotherapy. A
further 10 ml dose should be administered after 8 hours of the first dose. One
10 ml dose should be administered twice a day (every 12 hours) for 1-2 days
after completion of chemotherapy.

4-11 years: 5 ml (4 mg) Emistat Oral Solution should be taken 30 minutes

Pediatric before the start of chemotherapy. The other 2 doses should be taken 4 and 8
hours after the first dose. Then 5 ml oral solution should be administered 3
times a day (every 8 hours) for 1-2 days after completion of chemotherapy.

Radiotherapy induced Nausea and Vomiting

Age category Oral Solution

Adults/ Geriatric/ Child of 12 years or over
The recommended oral dosage is 10 ml (8 mg) Emistat Oral Solution 3 times
daily.
For total body irradiation, 10 ml (8-mg) Emistat Oral Solution should be
administered 1 to 2 hours before each fraction of radiotherapy administered
each day.
For single high-dose fraction radiotherapy to the abdomen, one 10 ml Emistat
Oral Solution should be administered 1 to 2 hours before radiotherapy, with
subsequent doses every 8 hours after the first dose for 1 to 2 days after
completion of radiotherapy.
For daily fractionated radiotherapy to the abdomen, 10 ml (8-mg) Emistat Oral
Solution should be administered 1 to 2 hours before radiotherapy, with
subsequent doses every 8 hours after the first dose for each day radiotherapy
is given.

Postoperative Nausea and Vomiting

Age category Oral Solution

Adults/ Geriatric/ Child of 12 years or over 20 ml (16 mg) Emistat Oral Solution 1 hour before induction of anesthesia

Dosage Adjustment for Patients With Impaired Renal Function: The dosage recommendation is the same as for the general population.
Dosage Adjustment for Patients With Impaired Hepatic Function: In patients with severe hepatic impairment, a single maximal daily dose of
8 mg to be infused over 15 minutes beginning 30 minutes before the start of the emetogenic chemotherapy is recommended.
Contraindication
Emistat® oral solution is contraindicated for patients known to have hypersensitivity to the drug.
Warnings
Hypersensitivity reactions have been reported in patients who have exhibited hypersensitivity to other selective 5-HT3 receptor antagonists.
Precautions
Ondansetron is not a drug that stimulates gastric or intestinal peristalsis. It should not be used instead of nasogastric suction. The use of
Ondansetron in patients following abdominal surgery or in patients with chemotherapy-induced nausea and vomiting may mask a progressive
ileus and/or gastric distension.
Interaction
Ondansetron does not itself appear to induce or inhibit the cytochrome P-450 drug-metabolizing enzyme system of the liver. Because
Ondansetron is metabolized by hepatic cytochrome P-450 drug-metabolizing enzymes, inducers or inhibitors of these enzymes may change
the clearance and hence, the half-life of Ondansetron. On the basis of available data, no dosage adjustment of Ondasetron is recommended
for patients on these drugs.
Carcinogenesis, Mutagenesis, Impairment of Fertility:
Carcinogenic effects were not seen in 2-year studies in rats and mice with oral Ondansetron doses up to 10 and 30 mg/kg per day,
respectively. Ondansetron was not mutagenic in standard tests for mutagenicity. Oral administration of Ondansetron up to 15 mg/kg per day
did not affect fertility or general reproduction performance of male and female rats.
Pregnancy, nursing mothers
Reproduction studies have been performed in pregnant rats and rabbits at daily oral doses up to 15 and 30 mg/kg per day, respectively, and
have revealed no evidence of impaired fertility or harm to the fetus due to Ondansetron. There are, however, no adequate and well-controlled
studies in pregnant women. Ondansetron is excreted in the breast milk of rats. So caution should be exercised when Ondansetron is
administered to a nursing women.
Pediatric Use:
Little information is available about dosage in pediatric patients 4 years of age or younger.
Geriatric Use:
Dosage adjustment is not needed in patients over the age of 65.
Adverse reactions:
Frequently reported adverse events were headache, constipation and diarrhea, but the majority have been mild or moderate in nature. In
chemotherapy-induced nausea and vomiting, rash has occurred in approximately 1% of patients receiving Ondansetron. There also have been
reports to a sensation of flushing or warmth, hiccups and liver enzyme abnormalities. Rare cases of anaphylaxis, brochospasm, tachycardia,
angina (chest pain), hypokalemia, shortness of breath have also been reported, except for bronchospasm and anaphylaxis, the relationship to
Emistat® is unclear. There have been no evidence to extrapyramidal reactions, in rare case oculogyric crisis appearing alone, as well as with
other dystonic reactions without definitive clinical evidence. In case of PONV, with the exception of headache, rates of these events were not
significantly different in the Ondansetron and placebo groups.
Overdose
There is no specific antidote for Ondansetron overdose. In addition to the adverse events, hypotension (and faintness) occurred in a patient
that took 60 ml of Emistat® oral solution. In all instances, the events resolved completely.
Packs
Emistat® oral solution: Each bottle contains 50 ml oral solution.

Storage
Store in a cool and dry place below 30 0 C. Protect from light.

Medicine: keep out of reach of children.

Manufactured for
Healthcare Pharmaceuticals Ltd.
Rajendrapur, Gazipur, Bangladesh
by Pharmasia Limited, Gazipur, Bangladesh. HP 52183